On February 5, 2026, Everest Medicines (HKEX: 1952) announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot") to commercialize MT1013 in China and the Asia-Pacific region (excluding Japan). According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million, as well as potential regulatory and commercial milestone payments of up to RMB 1.04 billion. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot.
MT1013 is the world's first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.
Han Kun acted as legal counsel to Everest Medicines in this transaction and provided comprehensive legal services throughout the process. The team was led by Yang (Aaron) Gu, comprising Fengqi (Franky) Yu, Lingyu Sheng and Jingjing Xu, and was deeply involved in key stages of the transaction, including the drafting and revision of the agreement. This project highlights Han Kun's outstanding capabilities in handling complex deals in the life sciences and healthcare sectors.
About Everest Medicines
Everest Medicines (HKEX: 1952.HK) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for global patients. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. Everest Medicines owns an industrial-scale global manufacturing site in Jiashan, Zhejiang Province, which is designed to be in full compliance with NMPA, EMA GMP, and WHO PQ standards. Everest Medicines' therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, Everest Medicines is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the company's website: www.everestmedicines.com.
About Micot
Shaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi'an in January 2007 and now operates in China (Xi'an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs. As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates. Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.
Han Kun's Life Sciences and Healthcare Practice
Han Kun is widely recognized and well-known for its practice in life sciences and healthcare. In relevant practice areas, we have been continuously ranked as a first-tier law firm by authoritative legal ranking agencies, including Chambers and Partners, The Legal 500, China Business Law Journal, Asialaw Profiles, etc. Han Kun is committed to providing clients with comprehensive legal services in life sciences and healthcare sector, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital market, pharmaceutical license in/out and asset sale/purchase transactions, intellectual property, data protection, compliance and regulatory, and dispute resolution. Han Kun has a dedicated life sciences and healthcare team led by multiple partners and comprised of tens of specialist attorneys. Our partners on the team all have served a broad range of both domestic and foreign clients and developed a deep understanding of industry regulatory requirements and commercial course of dealings. Our associates on the team are graduates from top law schools both in China and abroad, all fluent in Chinese and English and equipped with excellent legal writing skills. Han Kun is well aware of the importance of professional legal services for life sciences and healthcare companies, especially those facing complex legal issues and therefore requiring special legal support. Clients value our teamwork as we fully leverage the expertise and experience of our professionals, all experts in their respective fields. Our goal is always to provide clients with thorough and practical solutions and high-quality legal services.
